Report scope. This 2026 Drug Asset Due Diligence Report evaluates Ubamatamab as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Ubamatamab is a Bispecific T-cell Engager (BiTE) associated with CD3 x MUC16 and a global highest development stage of Phase 2. The lead disclosed indication is Advanced Lung Non-Small Cell Carcinoma. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Ubamatamab
- Target: CD3 x MUC16
- Lead indication: Advanced Lung Non-Small Cell Carcinoma
- Highest phase: Phase 2
- Matched trials: 6
- Matched result records: 7
- Matched asset deals: 1
Use PatSnap Life Sciences MCP servers to validate the Ubamatamab diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Ubamatamab, the MCP profile identifies CD3 x MUC16 as the primary target context and Advanced Lung Non-Small Cell Carcinoma as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Ubamatamab diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07637851 | Phase 1/2 | Not yet recruiting | Not disclosed | Not disclosed |
| NCT07502716 | Not Applicable | Available | Not disclosed | Not disclosed |
| NCT07154290 | Phase 2 | Recruiting | Not disclosed | Not disclosed |
| NCT06787612 | Phase 2 | Recruiting | Not disclosed | Not disclosed |
| NCT06444880 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT03564340 | Phase 1/2 | Recruiting | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Ubamatamab diligence evidence.
3. Clinical readouts: what is known
RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.
Study: RegeNovar (ASCO2026). Phase: Phase 1/2. Enrollment: 38. Published: 2026-05-29.
ORR = 25.0 % ( 5.6 - 58.2)
A phase 1/2 study of ubamatamab (REGN4018): low-grade serous ovarian cancer expansion cohort
Study: ESGO2026. Phase: Phase 1/2. Enrollment: 19. Published: 2026-02-28.
AE = The most common treatment-related adverse events (TRAEs) were neutropenia (68.4%) and cytokine release syndrome (31.6%).
546 Sarilumab as a potential mitigator of ubamatamab (MUC16×CD3)-induced cytokine release syndrome (CRS) in patients with advanced ovarian cancer (OC) or endometrial cancer (EC) | Journal for ImmunoTherapy of Cancer
Study: NCT03564340 (SITC2025). Phase: Phase 1/2. Enrollment: 239. Published: 2025-11-05.
CRS(Grade 1) = 12.5 % | CRS = 84.5 %
1078P - Randomised phase II study of ubamatamab ± cemiplimab in patients (pts) with platinum-resistant ovarian cancer (OC)
Study: NCT03564340 (ESMO2025). Phase: Phase 2. Enrollment: 150. Published: 2025-10-17.
ORR = 14.0 % | Med DOR = 10.5 Month ( 2.5–NE)
Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Study: NCT03564340 (ESMO 12023 | ESMO 22023). Phase: Phase 1. Enrollment: 35. Published: 2023-10-22.
DLT = In the highest dose cohort (450 mg), haemophagocytic lymphohistiocytosis (G4, DLT) was observed. | DLT = In the highest dose cohort (450 mg), haemophagocytic lymphohistiocytosis (G4, DLT) was observed.
41P - Phase 1 analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer
Study: NCT03564340 (ESMO_GCC2023). Phase: Phase 1. Enrollment: 78. Published: 2023-02-23.
TEAE = cytokine release syndrome (73.1%, all Grade 1/2) and pain (87.2%), primarily occurring in Weeks 1–2 of step-up dosing
523MO - Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
Study: NCT03564340 (ESMO2022). Phase: Phase 1. Enrollment: 78. Published: 2022-09-10.
TEAE(≥grade 3) = The most common Grade ≥3 TEAEs were anaemia (23.1%) and abdominal pain (19.2%). | TEAE(≥grade 3) = The most common Grade ≥3 TEAEs were anaemia (23.1%) and abdominal pain (19.2%).
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Ubamatamab diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Ubamatamab against approved therapies and clinical competitors in Advanced Lung Non-Small Cell Carcinoma, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Ubamatamab diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2021-04-28 | Sanofi disclosed its decision not to opt in on Regeneron’s REGN4018, REGN5459 or REGN5458. | Terminated | Collaboration | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Ubamatamab diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-14. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
